Researchers have discovered that a common form of high blood pressure is caused by tiny, non-cancerous growths in the adrenal ...

Lorundrostat is an orally-administered highly selective aldosterone synthase inhibitor that reduces aldosterone levels by inhibiting CYP11B2. The Launch-HTN trial (ClinicalTrials.gov Identifier: ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

Kyushu University researchers have uncovered a surprising layer of complexity in aldosterone-producing adenomas (APAs)-adrenal gland tumors that drive high blood pressure. Using cutting-edge analysis ...

Researchers have uncovered a surprising layer of complexity in aldosterone-producing adenomas -- adrenal gland tumors that drive high blood pressure. Using cutting-edge analysis techniques, they ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...